JP2020537645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537645A5 JP2020537645A5 JP2020520323A JP2020520323A JP2020537645A5 JP 2020537645 A5 JP2020537645 A5 JP 2020537645A5 JP 2020520323 A JP2020520323 A JP 2020520323A JP 2020520323 A JP2020520323 A JP 2020520323A JP 2020537645 A5 JP2020537645 A5 JP 2020537645A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- halo
- alkyl
- cyano
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 419
- 125000005843 halogen group Chemical group 0.000 claims description 240
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 125
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 110
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 99
- 125000000217 alkyl group Chemical group 0.000 claims description 98
- 229910052799 carbon Inorganic materials 0.000 claims description 68
- 125000005842 heteroatom Chemical group 0.000 claims description 59
- 229910052760 oxygen Inorganic materials 0.000 claims description 59
- 229910052717 sulfur Inorganic materials 0.000 claims description 59
- -1 cyano, hydroxyl Chemical group 0.000 claims description 58
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 125000004043 oxo group Chemical group O=* 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 17
- 150000001721 carbon Chemical group 0.000 claims description 13
- 208000019838 Blood disease Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000014951 hematologic disease Diseases 0.000 claims description 12
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 claims description 10
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 claims description 10
- 101000877314 Homo sapiens Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 10
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 206010011703 Cyanosis Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 229940124639 Selective inhibitor Drugs 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 2
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 claims description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 101150028321 Lck gene Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 2
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 claims description 2
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims description 2
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 19
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- SWKAVEUTKGKHSR-UHFFFAOYSA-N 3-(benzylsulfamoyl)-4-bromo-n-(4-bromophenyl)benzamide Chemical compound C1=CC(Br)=CC=C1NC(=O)C1=CC=C(Br)C(S(=O)(=O)NCC=2C=CC=CC=2)=C1 SWKAVEUTKGKHSR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 125000006193 alkinyl group Chemical group 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 38
- 150000001345 alkine derivatives Chemical class 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 125000002947 alkylene group Chemical group 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 0 CCC(C)=NC([*@](*)C1**1)=NC(*)=CN Chemical compound CCC(C)=NC([*@](*)C1**1)=NC(*)=CN 0.000 description 5
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- NCQZOTZKSQUJRS-UHFFFAOYSA-N CC(C)NCc1c[n](C)nc1 Chemical compound CC(C)NCc1c[n](C)nc1 NCQZOTZKSQUJRS-UHFFFAOYSA-N 0.000 description 1
- JAGQVVHJEKXLBZ-UHFFFAOYSA-N CCCC[n]1nnc(CNC)c1 Chemical compound CCCC[n]1nnc(CNC)c1 JAGQVVHJEKXLBZ-UHFFFAOYSA-N 0.000 description 1
- WZQVOACVRDDEJS-UHFFFAOYSA-N CCN(CC1)CC1C(NC)=O Chemical compound CCN(CC1)CC1C(NC)=O WZQVOACVRDDEJS-UHFFFAOYSA-N 0.000 description 1
- IANNBWVHGOIPRN-UHFFFAOYSA-N CNOCc1ccccc1 Chemical compound CNOCc1ccccc1 IANNBWVHGOIPRN-UHFFFAOYSA-N 0.000 description 1
- ZVLSNSQXNJVHMG-UHFFFAOYSA-N NOCC1CCCCC1 Chemical compound NOCC1CCCCC1 ZVLSNSQXNJVHMG-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024006712A JP2024038447A (ja) | 2017-10-17 | 2024-01-19 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573442P | 2017-10-17 | 2017-10-17 | |
| US62/573,442 | 2017-10-17 | ||
| US201862681804P | 2018-06-07 | 2018-06-07 | |
| US62/681,804 | 2018-06-07 | ||
| US201862746495P | 2018-10-16 | 2018-10-16 | |
| US201862746252P | 2018-10-16 | 2018-10-16 | |
| US62/746,495 | 2018-10-16 | ||
| US62/746,252 | 2018-10-16 | ||
| PCT/US2018/056333 WO2019079485A1 (en) | 2017-10-17 | 2018-10-17 | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006712A Division JP2024038447A (ja) | 2017-10-17 | 2024-01-19 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537645A JP2020537645A (ja) | 2020-12-24 |
| JP2020537645A5 true JP2020537645A5 (enExample) | 2021-10-07 |
| JP7425724B2 JP7425724B2 (ja) | 2024-01-31 |
Family
ID=66174630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520323A Active JP7425724B2 (ja) | 2017-10-17 | 2018-10-17 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
| JP2024006712A Pending JP2024038447A (ja) | 2017-10-17 | 2024-01-19 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006712A Pending JP2024038447A (ja) | 2017-10-17 | 2024-01-19 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200317642A1 (enExample) |
| EP (1) | EP3697419A4 (enExample) |
| JP (2) | JP7425724B2 (enExample) |
| CN (1) | CN111343988A (enExample) |
| AU (2) | AU2018350989A1 (enExample) |
| CA (1) | CA3079260A1 (enExample) |
| WO (1) | WO2019079485A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| US20210213014A1 (en) * | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| CN114650992A (zh) * | 2019-11-08 | 2022-06-21 | 赫普泰雅治疗有限公司 | Gpr52调节剂化合物 |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| AU2022415778A1 (en) * | 2021-12-14 | 2024-07-04 | Prazer Therapeutics Inc. | Novel compound for degrading target protein or polypeptide by using polyubiquitination |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2443305A (en) * | 1948-06-15 | Pyrimidine derivatives | ||
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| US7419984B2 (en) * | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| AU2004272288B2 (en) * | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| WO2010090875A1 (en) | 2009-01-21 | 2010-08-12 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
| BR112013005806B1 (pt) * | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| KR101682417B1 (ko) * | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
| CN105188371A (zh) * | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| IL307931A (en) * | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| MA47233A (fr) * | 2016-12-19 | 2019-10-23 | Epizyme Inc | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| WO2018195450A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
-
2018
- 2018-10-17 JP JP2020520323A patent/JP7425724B2/ja active Active
- 2018-10-17 CN CN201880072647.1A patent/CN111343988A/zh active Pending
- 2018-10-17 CA CA3079260A patent/CA3079260A1/en active Pending
- 2018-10-17 EP EP18869423.6A patent/EP3697419A4/en active Pending
- 2018-10-17 US US16/756,292 patent/US20200317642A1/en not_active Abandoned
- 2018-10-17 WO PCT/US2018/056333 patent/WO2019079485A1/en not_active Ceased
- 2018-10-17 AU AU2018350989A patent/AU2018350989A1/en not_active Abandoned
-
2023
- 2023-10-18 AU AU2023251449A patent/AU2023251449A1/en not_active Abandoned
-
2024
- 2024-01-19 JP JP2024006712A patent/JP2024038447A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504715A5 (enExample) | ||
| IL274936B2 (en) | Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2019513778A5 (enExample) | ||
| JP2022533398A5 (enExample) | ||
| IL295957A (en) | Compounds and methods for modulating splicing | |
| JP2011507849A5 (enExample) | ||
| JP2021512059A5 (enExample) | ||
| JP2019510798A5 (enExample) | ||
| JP2009532452A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2019529419A5 (enExample) | ||
| RU2013145310A (ru) | Диспиропирролидиновые производные | |
| JP2012523457A5 (enExample) | ||
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| CA2397558A1 (en) | Dosing regimen | |
| JP2009538897A5 (enExample) | ||
| JP2012524731A5 (enExample) | ||
| JP2022550099A5 (enExample) | ||
| JP2009543771A5 (enExample) | ||
| CA2530374A1 (en) | Hsp90 family protein inhibitors | |
| JP2020521739A5 (enExample) | ||
| JP2014515735A5 (enExample) | ||
| JP2020531414A5 (enExample) |